leadf
logo-loader
viewImmunoPrecise Antibodies Ltd

Immunoprecise shares now eligible for electronic clearing and settlement in the US

The antibody-focused company expects its new status will make trading of its shares in the US easier

A photo of man working in a lab
The company focuses on the next generation of antibody discovery

Immunoprecise Antibodies Ltd (OTCMKTS:IPATF) (CVE:IPA) climbed Thursday after announcing that its common shares are now eligible for electronic clearing and settlement through the Depository Trust Co in the US.

"The ability to have ImmunoPrecise shares electronically transferred between brokerages in the United States is significantly more convenient and reduces the costs incurred in trading shares," CFO Lisa Hebling said in a statement.

Shares of Immunoprecise gained US$0.03, or 5.2%, to US$0.58 on the OTC Markets. They traded at C$0.75 in Canada.

READ: ImmunoPrecise Antibodies clinches contract from Leidos Biomedical Research

DTC is a subsidiary of the Depository Trust & Clearing Corp, a US company that manages the electronic clearing and settlement of publicly traded companies. Securities eligible to be electronically cleared and settled through DTC are considered DTC-eligible.

The Victoria, British Columbia-based company expects such eligibility will simplify the process of trading and enhance liquidity of its common shares in the US.

Hebling added that “existing investors benefit from greater liquidity and execution speeds, while we've also opened the door to new investors that may have been previously restricted from our stock."

Immunoprecise focuses on the next generation of antibody discovery and operates from lab facilities located at the Vancouver Island Technology Park in Victoria, British Columbia.

Contact Dennis Fitzgerald at dennis@proactiveinvestors.com

Quick facts: ImmunoPrecise Antibodies Ltd

Price: 2.22 CAD

TSX-V:IPA
Market: TSX-V
Market Cap: $177.55 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of ImmunoPrecise Antibodies Ltd named herein, including the promotion by the Company of ImmunoPrecise Antibodies Ltd in any Content on the Site,...

FOR OUR FULL DISCLAIMER CLICK HERE

ImmunoPrecise Antibodies reveals 39% growth in 1Q revenue, initiates...

ImmunoPrecise Antibodies Ltd. (TSX-V:IPA) (OTCQB:IPATF) CEO Dr Jennifer Bath tells Proactive the technology platform company reported revenue increases by 39%, to $3.8 million in its first quarter financials, while the company initiates its pre-clinical coronavirus vaccine study. Bath says new...

3 weeks ago

2 min read